从资金流向上来看，当日医疗耗材供应链SPD板块主力资金净流出846.67万元，游资资金净流入8222.27 万元，散户资金净流出7375.6万元。医疗耗材供应链SPD板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 1.09亿 | 8.03% | - 4413.04万 | 3.26% | -1.53 Z | -11.29% | | 603716 | 塞力医疗 | 703.14万 | 3.25% | 408.98万 | 1.89% | -1112.12万 | -5.14% | | 603987 | 康德莱 | 427.31万 | 8.96% | -83.28万 | -1.75% | -344.02万 | -7.22% | | 301370 | 国科恒泰 | 132.11万 | 3.48% | 67.00万 | 1.76% | -199.10万 | -5.24% ...

证券日报网讯2月3日，塞力医疗（603716）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司股东总户数77208户。 ...

有投资者在互动平台向塞力医疗提问："公司连续亏损，有没有改善的决策，会不会被St。" 针对上述提问，塞力医疗回应称："尊敬的投资者，您好！公司正处于战略转型期，短期业绩承压受业 务结构调整、研发投入增加等多种因素影响，公司已制定并推进多项改善措施：通过深耕核心业务、强 化风控管理、推进智慧医疗创新、提升运营效能等措施，全力推动业绩稳步改善。公司目前未出现触及 退市风险警示的情形，感谢您对公司的关注！敬请广大投资者注意投资风险！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

本周关注点 截至2026年1月30日收盘，塞力医疗（603716）报收于22.12元，较上周的25.27元下跌12.47%。本周， 塞力医疗1月26日盘中最高价报26.46元。1月30日盘中最低价报22.07元。塞力医疗当前最新总市值46.5 亿元，在医药商业板块市值排名25/32，在两市A股市值排名3681/5184。 公司公告汇总 塞力斯医疗科技集团股份有限公司持股5%以上股东上海盎泽私募基金管理有限公司-盎泽太盈六号私募 证券投资基金，自2025年12月4日至2026年1月28日，通过集中竞价和大宗交易方式合计减持公司股份 3,091,200股，占公司总股本的1.47%。减持价格区间为19.64～22.00元/股，减持总金额65,226,349元。本 次减持计划已实施完毕，减持后上海盎泽持有公司股份9,009,199股，占公司总股本的4.29%，不再为持 股5%以上股东。减持行为符合相关法规及此前披露的减持计划。 塞力斯医疗科技集团股份有限公司预计2025年度归属于上市公司股东的净利润为-16,000万元到-20,900 万元，扣除非经常性损益后的净利润为-18,000万元到-23,000万元。业绩预亏 ...

从资金流向上来看，当日医疗耗材供应链SPD板块主力资金净流出2.31亿元，游资资金净流出1183.68万 元，散户资金净流入2.43亿元。医疗耗材供应链SPD板块个股资金流向见下表： 证券之星消息，1月30日医疗耗材供应链SPD板块较上一交易日下跌1.65%，塞力医疗领跌。当日上证指 数报收于4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗耗材供应链SPD板块个股涨 跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688329 | 文隆科技 | 25.01 | 3.69% | 2.18万 | 5401.67万 | | 603987 | 康德莱 | 9.26 | 0.43% | 5.85万 | 5399.36万 | | 000705 | 浙江震元 | 9.44 | 0.11% | 8.34万 | 7863.30万 | | 301126 | 达嘉维康 | 12.19 | 0.00% | 8.95万 | 1.08亿 | | 603122 | 合富中国 | ...

Group 1 - Jintian Co., Ltd. plans to increase its shareholding by an amount between 50 million to 100 million yuan [1] - Jinpu Garden expects a full-year loss of 260 million to 210 million yuan for 2025 [1] - Hebang Biotechnology's shareholder intends to reduce its holdings by no more than 2% of the repurchased shares [1] Group 2 - Shunbo Alloy has received an administrative regulatory decision from the Chongqing Securities Regulatory Bureau due to inaccurate financial disclosures [1] - Mars Man expects a loss of 370 million to 270 million yuan for 2025 [1] - Seli Medical anticipates a net loss of 160 million to 209 million yuan for the 2025 fiscal year [1] Group 3 - Hongchuan Wisdom expects a full-year loss of 475 million to 443 million yuan for 2025 [1] - Various convertible bonds are listed, including Haomei Convertible Bond which will not be forcibly redeemed [2] - New stocks from Meidel and other companies are set to be listed on the Beijing Stock Exchange and Shanghai Stock Exchange [1]

Core Viewpoint - The company, Saily Medical (603716.SH), has announced a projected net loss for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -160 million RMB and -209 million RMB [1] - The anticipated net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -180 million RMB and -230 million RMB [1] Strategic Focus - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [1] - There is an ongoing effort to consolidate and enhance the company's comprehensive competitiveness in the smart healthcare sector [1]

Core Viewpoint - The company, Saily Medical, anticipates a net profit loss of between 160 million to 209 million yuan for the entire year of 2025, primarily due to strategic shifts and operational challenges [1]. Group 1: Reasons for Performance Change - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [2]. - A decline in operating revenue is attributed to the transfer of certain controlling subsidiaries to enhance asset operation efficiency, resulting in these subsidiaries no longer being included in the consolidated financial statements [2]. - The company is undergoing a strategic transformation, with some business contracts not being renewed after expiration, compounded by industry policy impacts, leading to a significant decrease in operating revenue [2]. Group 2: Impact of R&D and Impairments - Increased R&D investment in the smart healthcare sector has negatively impacted profits [3]. - The company has been enhancing its collection efforts on receivables, but extended payment cycles from some clients have led to credit impairment losses [3]. - A decline in revenue and profit from certain subsidiaries has prompted the company to recognize impairment losses on goodwill associated with these subsidiaries [3]. Group 3: Financial Performance Indicators - For the first three quarters of 2025, the company's main revenue was 857 million yuan, a year-on-year decrease of 39.64%, with a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [3]. - In Q3 2025, the company reported a single-quarter main revenue of 274 million yuan, a decrease of 38.41% year-on-year, and a net profit attributable to shareholders of -31.12 million yuan, an increase of 39.27% year-on-year [3]. - The company’s financial metrics include a debt ratio of 49.61%, investment income of 7.34 million yuan, financial expenses of 34.98 million yuan, and a gross profit margin of 21.73% [3].

格隆汇1月29日丨塞力医疗（维权）(603716.SH)公布，经财务部门初步测算，预计2025年度实现归属于 上市公司股东的净利润为-16,000万元人民币到-20,900万元人民币；预计2025年度归属于上市公司股东 的扣除非经常性损益的净利润为-18,000万元人民币到-23,000万元人民币。公司本次业绩预亏的主要原 因为： 2、研发投入影响 公司持续加大在智慧医疗领域的研发投入，研发费用对利润造成一定影响。 （1）为聚焦核心业务发展，提升资产运营及使用效率，公司于2025年转让部分控股子公司，股权转让 后不再纳入合并范围，导致营业收入下降。（2）公司正处于战略转型，部分业务到期后未做续约安 排；外加行业政策的影响，致使公司营业收入出现一定幅度下降。2、研发投入影响公司持续加大在智 慧医疗领域的研发投入，研发费用对利润造成一定影响。 1、营业收入下降 ...

每经AI快讯，塞力医疗1月29日晚间发布业绩预告，公司预计2025年度实现归属于上市公司股东的净利 润为-1.6亿元人民币到-2.09亿元人民币，同比亏损减少4923.97万元人民币到23.97万元人民币。业绩变 动主要原因是，营业收入下降。为聚焦核心业务发展，提升资产运营及使用效率，公司于2025年转让部 分控股子公司，股权转让后不再纳入合并范围，导致营业收入下降。公司正处于战略转型，部分业务到 期后未做续约安排；外加行业政策的影响，致使公司营业收入出现一定幅度下降。研发投入影响。公司 持续加大在智慧医疗领域的研发投入，研发费用对利润造成一定影响。 每日经济新闻 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...